CasNo.220620-09-7,Tigecycline,(220620-09-7) Suppliers

10 Gram	Negotiable

Min.Order :10 Gram
Purity: 99%
Payment Terms : L/C,T/T,Other

Keywords

Tigecycline Tigecycline price 220620-09-7

Quick Details

Appearance:White powder
Application:Used as pharmaceutical intermediates
PackAge:Aluminous bag
ProductionCapacity:10000|Kilogram|Day
Storage:
Transportation:By Sea or By Air

Superiority:

Shanghai LONGBANG , Boasts strong competitive advantages by our well-trained chemists with rich professional backgroud. We aim to win the market via quick response and fast delivery, as well as continous development for high-tech medical compounds, bio-medicine, and new pharmaceutical intermediates.

- Our quality assurance system is based on GMP.

- Products are exported to all over the world: USA, Europe, South Asia, Middle East and so on, also has established long term and stable business relationships with our customers.

- Fast delivery

- High quality, Preferential price

Details:

Tigecycline

ProName: Tigecycline

Protein binding:71-89%

Metabolism:not metabolised

Half-life:42.4 hours

Excretion:59% biliary, 33% renal

CAS number:220620-09-7

ATC code:J01AA12

PubChem:CID 5282044

DrugBank:DB00560

ChemSpider:10482314

UNII:70JE2N95KR

KEGG:D01079

Formula:C29H39N5O8

Mol. mass:585.65 g/mol

Synonyms:N-[(5aR,6aS,7S,9Z,10aS)-9-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide

IUPAC:N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl]-2-(tert-butylamino)acetamide

Product information:

Tigecycline is the first drug in the glycylcycline class of antibiotics. Although it is structurally related to minocycline, alterations to the molecule resulted in its expanded spectrum of activity and decreased susceptibility to the development of resistance when compared with other tetracycline antibiotics. Tigecycline has a broad spectrum of activity, including activity against drug-resistant gram-positive organisms. Randomized trials have shown tigecycline to be efficacious for the treatment of complicated intraabdominal infections and complicated skin and skin structure infections. The dose of tigecycline is 50 mg intravenously every 12 hours after a 100-mg loading dose. Nausea, vomiting, and diarrhea were the most common adverse events reported with tigecycline therapy and may result in discontinuation of therapy.

Email: maggie@longbangsy.com